News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Vitae Pharmaceuticals, Inc. Announces Promising Data for VTP-4, Drug Candidate Advancing Toward Clinical Testing for the Treatment of Atherosclerosis


9/7/2012 10:29:00 AM

FORT WASHINGTON, Pa.--(BUSINESS WIRE)--Vitae Pharmaceuticals, a clinical-stage biopharmaceutical company discovering and developing novel, small molecule, best-in-class compounds, today announced the presentation of promising preclinical in vivo data for the Company’s Liver X Receptor (LXR) modulator, VTP-4, being studied for the treatment of atherosclerosis. VTP-4 is a potent and selective modulator of LXRß, activation of which has been shown to stimulate reverse cholesterol transport (RCT), to decrease vascular inflammation and to provide protection in several in vivo models of atherosclerosis.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES